Johnson & Johnson says ICOTYDE sustains psoriasis skin clearance through 2 years in Phase 3 ICONIC-TOTAL study

By Public Technologies
  • Johnson & Johnson disclosed new two-year Phase 3 ICONIC-TOTAL results for ICOTYDE (icotrokinra) in high-impact plaque psoriasis.
  • Results were already presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress 2026.
  • Data showed durable skin clearance in difficult-to-treat areas, supporting ICOTYDE’s positioning as a first-line systemic therapy.
  • Safety remained consistent with prior findings, with no new issues flagged over the two-year follow-up.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610020600PR_NEWS_USPR_____NY62204) on October 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.